Table of Contents
ISRN Hepatology
Volume 2014, Article ID 875140, 7 pages
http://dx.doi.org/10.1155/2014/875140
Clinical Study

Improved Serum Alpha-Fetoprotein Levels after Iron Reduction Therapy in HCV Patients

1Division of Hepatology, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, Shizuoka 431-3192, Japan
2Division of Respiratology, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, Shizuoka 431-3192, Japan

Received 4 September 2013; Accepted 9 December 2013; Published 10 February 2014

Academic Editors: A. Castiella, C. H. Hung, M. G. Mancino, and G. Sebastiani

Copyright © 2014 Hidenao Noritake et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. World Health Organization, “Hepatitis C,” Global Alert and Response, Geneva, Switzerland: World Health Organization, 2002, http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index.html.
  2. J. H. Hoofnagle, “Course and outcome of hepatitis C,” Hepatology, vol. 36, supplement 5, pp. S21–S29, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. L. B. Seeff, “Natural history of chronic hepatitis C,” Hepatology, vol. 36, supplement 5, pp. S35–S46, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. Y. Sato, K. Nakata, Y. Kato et al., “Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein,” The New England Journal of Medicine, vol. 328, no. 25, pp. 1802–1806, 1993. View at Publisher · View at Google Scholar · View at Scopus
  5. P. J. Johnson, “The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma,” Clinics in Liver Disease, vol. 5, no. 1, pp. 145–159, 2001. View at Google Scholar · View at Scopus
  6. K.-Q. Hu, N. L. Kyulo, N. Lim, B. Elhazin, D. J. Hillebrand, and T. Bock, “Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma,” The American Journal of Gastroenterology, vol. 99, no. 5, pp. 860–865, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. C.-W. Chu, S.-J. Hwang, J.-C. Luo et al., “Clinical, virologic, and pathologic significance of elevated serum alpha-fetoprotein levels in patients with chronic hepatitis C,” Journal of Clinical Gastroenterology, vol. 32, no. 3, pp. 240–244, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. A. M. Di Bisceglie, R. K. Sterling, R. T. Chung et al., “Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial,” Journal of Hepatology, vol. 43, no. 3, pp. 434–441, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. M. W. Fried, M. L. Shiffman, K. Rajender Reddy et al., “Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection,” The New England Journal of Medicine, vol. 347, no. 13, pp. 975–982, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. K. Ikeda, Y. Arase, S. Saitoh et al., “Prediction model of hepatocarcinogenesis for patients with hepatitis C virus-related cirrhosis: validation with internal and external cohorts,” Journal of Hepatology, vol. 44, no. 6, pp. 1089–1097, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. N. Akuta, F. Suzuki, Y. Kawamura et al., “Substitution of amino acid 70 in the hepatitis C virus core region of genotype 1b is an important predictor of elevated alpha-fetoprotein in patients without hepatocellular carcinoma,” Journal of Medical Virology, vol. 80, no. 8, pp. 1354–1362, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. A.-C. Cardoso, R. Moucari, C. Figueiredo-Mendes et al., “Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis,” Journal of Hepatology, vol. 52, no. 5, pp. 652–657, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Murashima, M. Tanaka, M. Haramaki et al., “A decrease in AFP level related to administration of interferon in patients with chronic hepatitis C and a high level of AFP,” Digestive Diseases and Sciences, vol. 51, no. 4, pp. 808–812, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. Arase, K. Ikeda, F. Suzuki et al., “Prolonged-interferon therapy reduces hepatocarcinogenesis in aged-patients with chronic hepatitis C,” Journal of Medical Virology, vol. 79, no. 8, pp. 1095–1102, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. T.-M. Chen, P.-T. Huang, M.-H. Tsai et al., “Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy,” Journal of Gastroenterology and Hepatology, vol. 22, no. 5, pp. 669–675, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. N. Akuta, F. Suzuki, Y. Kawamura et al., “Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy,” Journal of Medical Virology, vol. 80, no. 8, pp. 1363–1369, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. M.-L. Yu, S.-M. Lin, W.-L. Chuang et al., “A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan,” Antiviral Therapy, vol. 11, no. 8, pp. 985–994, 2006. View at Google Scholar · View at Scopus
  18. J. Kato, K. Miyanishi, M. Kobune et al., “Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C,” Journal of Gastroenterology, vol. 42, no. 10, pp. 830–836, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Franchini, G. Targher, F. Capra, M. Montagnana, and G. Lippi, “The effect of iron depletion on chronic hepatitis C virus infection,” Hepatology International, vol. 2, no. 3, pp. 335–340, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. C.-T. Wai, J. K. Greenson, R. J. Fontana et al., “A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C,” Hepatology, vol. 38, no. 2, pp. 518–526, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. P. J. Johnson, “The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma,” Clinics in Liver Disease, vol. 5, no. 1, pp. 145–159, 2001. View at Google Scholar · View at Scopus
  22. K.-Q. Hu, N. L. Kyulo, N. Lim, B. Elhazin, D. J. Hillebrand, and T. Bock, “Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma,” The American Journal of Gastroenterology, vol. 99, no. 5, pp. 860–865, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. C.-W. Chu, S.-J. Hwang, J.-C. Luo et al., “Clinical, virologic, and pathologic significance of elevated serum alpha-fetoprotein levels in patients with chronic hepatitis C,” Journal of Clinical Gastroenterology, vol. 32, no. 3, pp. 240–244, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Taniguchi, Y. Iwasaki, A. Fujiwara et al., “Long-term monitoring of platelet count, as a non-invasive marker of hepatic fibrosis progression and/or regression in patients with chronic hepatitis C after interferon therapy,” Journal of Gastroenterology and Hepatology, vol. 21, no. 1, pp. 281–287, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. E. Ono, Y. Shiratori, T. Okudaira et al., “Platelet count reflects stage of chronic hepatitis C,” Hepatology Research, vol. 15, no. 3, pp. 192–200, 1999. View at Publisher · View at Google Scholar · View at Scopus
  26. C.-T. Wai, J. K. Greenson, R. J. Fontana et al., “A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C,” Hepatology, vol. 38, no. 2, pp. 518–526, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. S.-N. Lu, J.-H. Wang, S.-L. Liu et al., “Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma,” Cancer, vol. 107, no. 9, pp. 2212–2222, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. L. Dollé, J. Best, J. Mei et al., “The quest for liver progenitor cells: a practical point of view,” Journal of Hepatology, vol. 52, no. 1, pp. 117–129, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. K. N. Lowes, B. A. Brennan, G. C. Yeoh, and J. K. Olynyk, “Oval cell numbers in human chronic liver diseases are directly related to disease severity,” The American Journal of Pathology, vol. 154, no. 2, pp. 537–541, 1999. View at Google Scholar · View at Scopus
  30. L. Libbrecht, V. Desmet, B. Van Damme et al., “Deep intralobular extension of human hepatic “progenitor cells” correlates with parenchymal inflammation in chronic viral hepatitis: can “progenitor cells” migrate?” Journal of Pathology, vol. 192, no. 3, pp. 373–378, 2000. View at Google Scholar
  31. J. A. Eleazar, L. Memeo, J. S. Jhang et al., “Progenitor cell expansion: an important source of hepatocyte regeneration in chronic hepatitis,” Journal of Hepatology, vol. 41, no. 6, pp. 983–991, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Fotiadu, V. Tzioufa, E. Vrettou, D. Koufogiannis, C. S. Papadimitriou, and P. Hytiroglou, “Progenitor cell activation in chronic viral hepatitis,” Liver International, vol. 24, no. 3, pp. 268–274, 2004. View at Google Scholar · View at Scopus
  33. A. D. Clouston, E. E. Powell, M. J. Walsh, M. M. Richardson, A. J. Demetris, and J. R. Jonsson, “Fibrosis correlates with a ductular reaction in hepatitis C: roles of impaired replication, progenitor cells and steatosis,” Hepatology, vol. 41, no. 4, pp. 809–818, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Sartori, S. Andorno, C. Rigamonti, and R. Baldoroni, “Chronic hepatitis C treated with phlebotomy alone: biochemical and histological outcome,” Digestive and Liver Disease, vol. 33, no. 2, pp. 157–162, 2001. View at Google Scholar · View at Scopus
  35. N. Tanaka, A. Horiuchi, T. Yamaura, M. Komatsu, E. Tanaka, and K. Kiyosawa, “Efficacy and safety of 6-month iron reduction therapy in patients with hepatitis C virus-related cirrhosis: a pilot study,” Journal of Gastroenterology, vol. 42, no. 1, pp. 49–55, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. Y. Yoshida, Y. Imai, Y. Sawai et al., “Hydroxyoctadecadienoic acid as a potential biomarker for oxidative stress in patients with chronic hepatitis C,” Journal of Gastroenterology and Hepatology, vol. 25, no. 1, pp. 107–115, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. L. Libbrecht, “Hepatic progenitor cells in human liver tumor development,” World Journal of Gastroenterology, vol. 12, no. 39, pp. 6261–6265, 2006. View at Google Scholar · View at Scopus
  38. H. C. Isom, E. I. McDevitt, and M. S. Moon, “Elevated hepatic iron: a confounding factor in chronic hepatitis C,” Biochimica et Biophysica Acta, vol. 1790, no. 7, pp. 650–662, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Franchini, G. Targher, F. Capra, M. Montagnana, and G. Lippi, “The effect of iron depletion on chronic hepatitis C virus infection,” Hepatology International, vol. 2, no. 3, pp. 335–340, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. H. Zhang and H. J. Forman, “Redox regulation of γ-glutamyl transpeptidase,” The American Journal of Respiratory Cell and Molecular Biology, vol. 41, no. 5, pp. 509–515, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. C. Ravuri, G. Svineng, S. Pankiv, and N.-E. Huseby, “Endogenous production of reactive oxygen species by the NADPH oxidase complexes is a determinant of γ-glutamyltransferase expression,” Free Radical Research, vol. 45, no. 5, pp. 600–610, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. L. C. E. Ohlson, L. Koroxenidou, and I. P. Hällström, “Inhibition of in vivo rat liver regeneration by 2-acetylaminofluorene affects the regulation of cell cycle-related proteins,” Hepatology, vol. 27, no. 3, pp. 691–696, 1998. View at Publisher · View at Google Scholar · View at Scopus
  43. B. Lindeman, E. Skarpen, M. P. Oksvold et al., “The carcinogen 2-acetylaminofluorene inhibits activation and nuclear accumulation of cyclin-dependent kinase 2 in growth-induced rat liver,” Molecular Carcinogenesis, vol. 27, no. 3, pp. 190–199, 2000. View at Google Scholar
  44. A. B. Schroeijers, G. L. Scheffer, M. J. Flens et al., “Immunohistochemical detection of the human major vault protein LRP with two monoclonal antibodies in formalin-fixed, paraffin-embedded tissues,” The American Journal of Pathology, vol. 152, no. 2, pp. 373–378, 1998. View at Google Scholar · View at Scopus
  45. T. Roskams, S. Q. Yang, A. Koteish et al., “Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease,” The American Journal of Pathology, vol. 163, no. 4, pp. 1301–1311, 2003. View at Google Scholar · View at Scopus
  46. T. J. Liang and M. G. Ghany, “Current and future therapies for hepatitis C virus infection,” The New England Journal of Medicine, vol. 368, no. 20, pp. 1907–1917, 2013. View at Google Scholar
  47. A. C. G. Chua, B. Klopcic, I. C. Lawrance, J. K. Olynyk, and D. Trinder, “Iron: an emerging factor in colorectal carcinogenesis,” World Journal of Gastroenterology, vol. 16, no. 6, pp. 663–672, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. J. E. Tirnitz-Parker, A. Glanfield, J. K. Olynyk et al., “Iron and hepatic carcinogenesis,” Critical Reviews in Oncogenesis, vol. 18, no. 5, pp. 391–407, 2013. View at Google Scholar
  49. A. Asberg, K. Thorstensen, W. Irgens et al., “Cancer risk in HFE C282Y homozygotes: results from the HUNT 2 study,” Scandinavian Journal of Gastroenterology, vol. 48, no. 2, pp. 189–195, 2013. View at Google Scholar
  50. D. Galaris, V. Skiada, and A. Barbouti, “Redox signaling and cancer: the role of “labile” iron,” Cancer Letters, vol. 266, no. 1, pp. 21–29, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. S. Toyokuni, “Persistent oxidative stress in cancer,” FEBS Letters, vol. 358, no. 1, pp. 1–3, 1995. View at Publisher · View at Google Scholar · View at Scopus